Skip to content

Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases and announcements published by the company in 2008. The releases and announcements are available on the internet website of Orion Corporation, at www.orion.fi/investors. Orion points out that part of the information in the releases can have become out-dated.
 
Stock Exchange Releases in 2008
02.01.2008 

 
Orion comments on new challenge by Sun Pharmaceutical Industries Ltd., India, of Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo® in the United States
24.01.2008 
  
Positive primary endpoint from FIRST-STEP study with Stalevo® in early Parkinson's Disease
30.01.2008 
 
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation
07.02.2008   
Orion Group Financial Review of 2007
07.02.2008   
Matters to be handled at Orion's AGM on 25 March 2008
07.02.2008
   
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007
07.02.2008 
 
Orion sues Sun Pharmaceuticals in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Stalevo®
25.02.2008   
Orion Oyj: GTx announced Phase III clinical data for toremifene citrate 80 mg
28.02.2008   
Orion Group Annual Report 2007 published
25.03.2008   
Orion Corporation: Decisions by the AGM on 25 March 2008
25.03.2008 
  
Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees
15.04.2008   
Orion seeking broader indication for Stalevo®
25.04.2008   
Orion Group Interim Report 1-3/2008
09.05.2008   
Orion has decided not to continue the development of a new COMT inhibitor candidate
05.08.2008   
Orion Group Interim Report 1-6/2008
12.09.2008   
Orion updates progress with dexmedetomidine trials
07.10.2008 
  
Orion comments on new ANDA by Sun Pharma Global, Inc. for generic entacapone (Orion's proprietary drug Comtan®) in the United States
28.10.2008   
Orion Group Interim Report 1-9/2008
28.10.2008   
Orion Corporation's publication schedules for financial reporting in 2009
29.10.2008
Composition of the Nomination Committee of Orion Corporation
03.11.2008 
 
Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® in the United States
12.11.2008
Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan®
19.11.2008 
         
Orion to renew operational model of pharmaceutical R&D. Negotiation proposal on reduction of up to 300 employees in Finland
08.12.2008 
 
Orion sues Wockhardt USA, Inc. and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo®
11.12.2008 

 
Orion comments on ANDA filed by Wockhardt Limited for a generic version of Orion's proprietary drug Stalevo® (25/200/100; 37.5/200/150 and 50/200/200 mg strengths) in the United States
 
Stock Exchange Announcements in 2008
16.01.2008   
Orion Corporation publishes 2007 Financial Statement release on 7 Feb 2008 at 8.30 EET
28.01.2008   
98,020 Orion A-shares converted into B-shares
18.03.2008   
Orion Corporation acquisition of own shares 17.3.2008
19.03.2008   
Orion Corporation acquisition of own shares 18.3.2008
20.03.2008   
Orion Corporation acquisition of own shares 19.3.2008
20.03.2008   
Orion Corporation: Transfer of own shares
17.04.2008   
Orion Corporation publishes Interim Report Q1/2008 on 25 April 2008
16.06.2008   
520,000 Orion A-shares converted into B-shares
23.07.2008 
Orion Corporation publishes Interim Report Q2/2008 on 5 August 2008
28.07.2008 
500,000 Orion A-shares converted into B-shares
17.10.2008   
Orion publishes Interim Report 1-9/2008 on 28 Oct 2008
 
 
Orion Corporation
 
 
 
Timo Lappalainen            Olli Huotari
President and CEO         Senior VP, Corporate Functions
 
 
ABOUT ORION
Orion is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. In 2007, Orion generated net sales of EUR 683.6 million and invested EUR 98.5 million in research and development. In the end of 2008, the number of employees in the Orion Group was approximately 3,300, of which 2,700 persons were working in Finland. Orion corporate headquarters are in Espoo, Finland.  For more information, please visit  http://www.orion.fi/english/. The financial statements of the Orion Group for 2008 will be published on 6 February 2009.
 
 
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi